Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, May 19 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced changes to its 18th and 20th Restricted Stock Unit (RSU) programs based on stock issuance completed on May 18, 2026.
Due to four individuals losing their eligibility, the number of shares to be issued decreased. Originally planned to issue 736,190 common shares, the company now plans to issue fewer shares: For the 18th RSU program, instead of issuing 208,977 shares, the company will issue 208,483 shares. Similarly, for the 20th RSU program, the issuance will decrease from 527,213 shares to 521,075 shares. The total amount raised through the issuance also changed accordingly.
Previously, the total issuance value was expected to be ¥211.3 million for the 18th RSU and ¥533.0 million for the 20th RSU. Now, the total issuance value for the 18th RSU is ¥210.8 million and for the 20th RSU is ¥526.8 million. The shares will be distributed among two directors/executives for the 18th RSU and three for the 20th RSU, along with employees of the parent company and subsidiaries. The reduction affects a total of 288 recipients across both RSU programs compared to the initial plan of 348.
Nxera Pharma continues to focus on developing innovative specialty medicines addressing unmet needs in neurology, metabolic diseases, and immunology, leveraging its proprietary NxWave™ drug discovery platform.
🟢 Confidence: High AI-translated content.